Comparative Pharmacology
Head-to-head clinical analysis: DIATRIZOATE 60 versus GASTROGRAFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIATRIZOATE 60 versus GASTROGRAFIN.
DIATRIZOATE-60 vs GASTROGRAFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diatrizoate is an ionic, monomeric, high-osmolar iodinated contrast agent that absorbs X-rays due to its iodine content, enhancing radiographic imaging by attenuating X-ray beams. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
Gastrografin is a water-soluble iodinated contrast agent that increases the radiodensity of the gastrointestinal tract, allowing visualization on X-ray. It acts by absorbing X-rays due to its high iodine content.
1-2 mL/kg IV bolus up to 150 mL total for contrast-enhanced CT; repeat doses may be given based on imaging needs.
Oral or rectal: 50-100 mL of a 1:1 dilution with water (or full strength as needed) for CT or fluoroscopic studies. Typically single dose.
None Documented
None Documented
Terminal half-life approximately 1-2 hours in patients with normal renal function. Prolonged in renal impairment (up to 20-30 hours in anuria).
Terminal elimination half-life: 1-2 hours (for absorbed diatrizoate); prolongation in renal impairment (up to 20 hours in anuria).
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Negligible biliary or fecal elimination.
Renal: 80-90% (glomerular filtration, unchanged); Biliary/Fecal: <5% (minor biliary excretion of absorbed fraction).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent